Physician profile
Franklin E Ellenson
NPI 1780622423
$2,292.83
in general payments reported to CMS, 2019-2025
31 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $61.58 · 2021: $113 · 2022: $52.52 · 2023: $443 · 2024: $707 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.49 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $293.30 | 2019-2025 | Mavenclad |
| Eisai INC. | $218.90 | 2023-2025 | |
| Lundbeck LLC | $216.42 | 2024-2025 | Vyepti, Rexulti |
| Abbvie INC. | $191.24 | 2021-2025 | |
| Pfizer INC. | $160.29 | 2023-2025 | |
| Genentech USA, INC. | $145.96 | 2019-2024 | Ocrevus |
| Tg Therapeutics, INC. | $129.79 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $124.00 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Argenx US, INC. | $118.80 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sunovion Pharmaceuticals INC. | $103.82 | 2019-2021 | |
| Biogen, INC. | $65.36 | 2020-2023 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $60.13 | 2023-2025 | Nayzilam, Fintepla |
| Acadia Pharmaceuticals INC | $53.26 | 2019-2024 | Nuplazid |
| Allergan, INC. | $38.70 | 2019 | |
| Ge Healthcare | $34.58 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $32.52 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $31.12 | 2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $30.37 | 2024 | Hyqvia |
| Catalyst Pharmaceuticals, INC. | $26.91 | 2021 | |
| Tms Neurohealth Centers INC. | $24.76 | 2025 | Tms Neurohealth Centers INC. |
| Vanda Pharmaceuticals INC. | $24.54 | 2025 | Ponvory |
| Sarepta Therapeutics, INC. | $23.03 | 2019 | |
| Csl Behring | $21.43 | 2024 | Hizentra |
| Nevro Corp. | $21.12 | 2020 | |
| Neurelis, INC. | $19.85 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $17.41 | 2024 | Onpattro |
| Alexion Pharmaceuticals, INC. | $15.78 | 2019 | |
| Horizon Therapeutics Plc | $13.74 | 2023 | Uplizna |
| Inspire Medical Systems, INC. | $13.08 | 2023 | Inspire |
| Amneal Pharmaceuticals LLC | $11.49 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Ellenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.